Literature DB >> 12029460

Successful resumption of trimethoprim-sulfamethoxazole after oral desensitisation in patients with chronic granulomatous disease.

Masafumi Hasui1, Fumiko Kotera, Shoji Tsuji, Akemi Yamamoto, Shoichiro Taniuchi, Yasuhiro Fujikawa, Mitsuru Nakajima, Akira Yoshioka, Yohnosuke Kobayashi.   

Abstract

Two patients with chronic granulomatous disease who had previously been intolerant to trimethoprim-sulfamethoxazole because of various adverse reactions completed a desensitisation protocol with a favourable clinical outcome.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12029460     DOI： 10.1007/s00431-002-0944-6

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  5 in total

Review 1.  Chronic granulomatous disease.

Authors:  D Goldblatt; A J Thrasher
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

2.  Rapid oral desensitization to trimethoprim-sulfamethoxazole in infants and children.

Authors:  V J Palusci; A Kaul; R M Lawrence; K A Haines; P L Kwittken
Journal:  Pediatr Infect Dis J       Date:  1996-05       Impact factor: 2.129

3.  A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S.

Authors:  S Yoshizawa; A Yasuoka; Y Kikuchi; M Honda; H Gatanaga; N Tachikawa; Y Hirabayashi; S Oka
Journal:  Ann Allergy Asthma Immunol       Date:  2000-09       Impact factor: 6.347

4.  Treatment of seven cases of chronic granulomatous disease with sulfamethoxazole-trimethoprim (SMX-TMP).

Authors:  Y Kobayashi; D Amano; K Ueda; Y Kagosaki; T Usui
Journal:  Eur J Pediatr       Date:  1978-04-20       Impact factor: 3.183

5.  Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients.

Authors:  M T Nguyen; P J Weiss; M R Wallace
Journal:  AIDS       Date:  1995-06       Impact factor: 4.177
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.